The Need for Ocular Matrix Biomarker Analysis

Research in the area of ophthalmology-relevant molecular biomarker identification is ongoing. These molecules may aid in the early detection of disease, predict disease severity and the rate of disease progression, and monitor response to treatment. Compared with other biomarkers, biomarkers in the eye have the advantage of obtaining a variety of ocular matrices by minimally invasive methods. In addition, repeated sampling for biomarker evaluation has enabled reproducible objective measures of the disease process or biological responses to a drug treatment. In animal models of eye disease, various ocular matrixes and biomarkers can be collected and analyzed, thereby ensuring a successful drug development process. Today, the most studied ocular matrixes for the identification of biomarkers are tears, conjunctival cells, AH, and the vitreous. The evaluation of these matrixes has provided valuable insight into diagnosis of disease, progression or modulation of disease with and without pharmaceutical intervention. This makes ophthalmic biomarker assessment a critical component of ophthalmic drug discovery and development.

Fig. 1. The main workflow for current mass spectrometry-based tear proteomics techniques. (Shabbir A, et al., 2021)

Why Choose Ace Therapeutics' Ocular Matrix Biomarker Discovery and Analysis Services?

As a comprehensive ophthalmology solutions provider, Ace Therapeutics supports all your ophthalmology research. Our experienced team of ophthalmology and biomarkers experts provides comprehensive ocular matrix biomarker discovery and analysis services for global customers. This will help customers screen any biomarkers that may help your research, whether they are specific molecules in any ocular matrix such as proteins, gene sequences, or expressed RNA.

With the help of advanced analysis platforms, our scientists have used a wide range of technologies and methods to study and discover ocular matrix biomarkers. They are proteomics, mass spectrometry, genomics, metabolomics, lipidomics and epigenetic approaches, etc.

Do you want to identify new biomarkers? We accelerate your research from hypothesis to candidate validation! Ace Therapeutics provides the following ocular matrix biomarker discovery and analysis solutions, including but not limited to:

• Tear Fluid Biomarker Identification and Analysis Services >>
• Conjunctival Biomarker Identification and Analysis Services >>
• Aqueous Humour Biomarker Identification and Analysis Services >>
• Vitreous Biomarkers Identification and Analysis Services >>

Explore Our Capabilities

• LC-MS, including SELDI-TOF-MS, MALDI-TOF-MS and 2D-nanoLC-MS/MS.
• Flow cytometry.
• Reverse transcriptase polymerase chain reaction (RT-PCR).
• RNA sequencing (RNA-Seq).
• Impression cytology.
• Enzyme-linked immunosorbent assay (ELISA).
• In vivo confocal microscopy (IVMC) analysis.
• Bioinformatics analysis.

Why Choose Us?

• Provide powerful detection methods and analysis methods that can be easily transferred across multiple platforms.
• Provide mechanism-of-action studies that can be linked to new therapeutic targets.
• Across multiple eye disease areas.

Thanks to strong professional knowledge and an advanced technology platform, Ace Therapeutics offers comprehensive ocular matrix biomarker discovery and analysis services. Our experienced team of ophthalmology and biomarkers experts will determine the most appropriate solution for your project based on your specific requirements. If you are interested in our services, please feel free to contact us.

References

1. Tamhane M, Cabrera-Ghayouri S, Abelian G, et al. Review of Biomarkers in Ocular Matrices: Challenges and Opportunities. Pharm Res. 2019;23;36(3):40.
2. Zhan X, Li J, Guo Y, et al. Mass spectrometry analysis of human tear fluid biomarkers specific for ocular and systemic diseases in the context of 3P medicine. EPMA J. 2021;3;12(4):449-475.

• Omics-Based Ocular Biomarker Discovery and Analysis Services
• Ocular Imaging Biomarker Services
• Ocular Predictive Biomarker Identification Services
• Ocular Prognosis Biomarker Services
• Ocular Transformational Biomarker Services
• Ocular Pharmacodynamic Biomarker Services
• Custom Ocular Biomarker Development Services

• * Name:
• Phone:
• * Email:
• * Services or Products of Interest:
• Project Description:
• * All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

  * Tick to confirm the Research Use Only (RUO) statement.

• Submit